153 related articles for article (PubMed ID: 17092839)
21. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
[TBL] [Abstract][Full Text] [Related]
22. Interaction of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates with human liver microsomal cytochromes P450: comparison with free doxorubicin.
Masek V; Anzenbacherová E; Etrych T; Strohalm J; Ulbrich K; Anzenbacher P
Drug Metab Dispos; 2011 Sep; 39(9):1704-10. PubMed ID: 21642392
[TBL] [Abstract][Full Text] [Related]
23. Self-association properties of HPMA copolymers containing an amphipathic heptapeptide.
Ding H; Kopecková P; Kopecek J
J Drug Target; 2007; 15(7-8):465-74. PubMed ID: 17671893
[TBL] [Abstract][Full Text] [Related]
24. Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates.
Paul A; Vicent MJ; Duncan R
Biomacromolecules; 2007 May; 8(5):1573-9. PubMed ID: 17419585
[TBL] [Abstract][Full Text] [Related]
25. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting.
Li L; Yang Q; Zhou Z; Zhong J; Huang Y
Biomaterials; 2014 Jun; 35(19):5171-87. PubMed ID: 24702960
[TBL] [Abstract][Full Text] [Related]
27. The same drug but a different mechanism of action: comparison of free doxorubicin with two different N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugates in EL-4 cancer cell line.
Kovár L; Strohalm J; Chytil P; Mrkvan T; Kovár M; Hovorka O; Ulbrich K; Ríhová B
Bioconjug Chem; 2007; 18(3):894-902. PubMed ID: 17402705
[TBL] [Abstract][Full Text] [Related]
28. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy.
Etrych T; Kovář L; Strohalm J; Chytil P; Ríhová B; Ulbrich K
J Control Release; 2011 Sep; 154(3):241-8. PubMed ID: 21699933
[TBL] [Abstract][Full Text] [Related]
29. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles.
Zhou Z; Li L; Yang Y; Xu X; Huang Y
Biomaterials; 2014 Aug; 35(24):6622-35. PubMed ID: 24814427
[TBL] [Abstract][Full Text] [Related]
30. Novel star HPMA-based polymer conjugates for passive targeting to solid tumors.
Etrych T; Strohalm J; Chytil P; Říhová B; Ulbrich K
J Drug Target; 2011 Dec; 19(10):874-89. PubMed ID: 21978286
[TBL] [Abstract][Full Text] [Related]
31. New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting.
Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Boucek J; Ríhová B; Ulbrich K
J Control Release; 2008 Apr; 127(2):121-30. PubMed ID: 18304673
[TBL] [Abstract][Full Text] [Related]
32. N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour targeting. Synthesis by RAFT polymerisation and physicochemical characterisation.
Chytil P; Etrych T; Kříž J; Subr V; Ulbrich K
Eur J Pharm Sci; 2010 Nov; 41(3-4):473-82. PubMed ID: 20696244
[TBL] [Abstract][Full Text] [Related]
33. HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro.
Kovár M; Kovár L; Subr V; Etrych T; Ulbrich K; Mrkvan T; Loucká J; Ríhová B
J Control Release; 2004 Sep; 99(2):301-14. PubMed ID: 15380639
[TBL] [Abstract][Full Text] [Related]
34. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
Ríhová B; Strohalm J; Hovorka O; Subr V; Etrych T; Chytil P; Pola R; Plocová D; Boucek J; Ulbrich K
J Control Release; 2008 Apr; 127(2):110-20. PubMed ID: 18325618
[TBL] [Abstract][Full Text] [Related]
35. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
36. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro.
Omelyanenko V; Gentry C; Kopecková P; Kopecek J
Int J Cancer; 1998 Feb; 75(4):600-8. PubMed ID: 9466663
[TBL] [Abstract][Full Text] [Related]
37. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
38. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
[TBL] [Abstract][Full Text] [Related]
39. HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.
Etrych T; Subr V; Strohalm J; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2012 Dec; 164(3):346-54. PubMed ID: 22759979
[TBL] [Abstract][Full Text] [Related]
40. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
Luo Y; Bernshaw NJ; Lu ZR; Kopecek J; Prestwich GD
Pharm Res; 2002 Apr; 19(4):396-402. PubMed ID: 12033370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
